Literature DB >> 29922825

Ertugliflozin for Type 2 Diabetes.

.   

Abstract

Entities:  

Year:  2018        PMID： 29922825     DOI： 10.1001/jama.2018.5840

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  3 in total

1.  Canagliflozin should be prescribed with caution to individuals with type 2 diabetes and high risk of amputation.

Authors:  Matilde Monteiro-Soares; Inês Ribeiro-Vaz; Edward J Boyko
Journal:  Diabetologia       Date:  2019-04-02       Impact factor: 10.122

Review 2.  Effect of ertugliflozin on glycemic levels, blood pressure and body weight of patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  Maryam Zaman; Roha Saeed Memon; Arooba Amjad; Tehlil Rizwan; Jai Kumar; Ibtehaj Ul Haque; Syed Saad Ali; Lin Li; Muhammad Shariq Usman
Journal:  J Diabetes Metab Disord       Date:  2020-09-03

3.  Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Jing Huang; Shuyuan Xiong; Shenglan Ding; Qingfeng Cheng; Zhiping Liu
Journal:  J Diabetes Res       Date:  2020-12-14       Impact factor: 4.011
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.